Abstract:331 Purpose: Pancreatic cancer (PcCa) is one of the primary causes of death from cancer in the developed countries and always exhibits poor prognosis. Early detection and intervention are of great demand clinically in PcCa. Non-invasive targeting imaging is a promising strategy for the diagnosis and monitoring of PcCa. In this study, we applied near-infrared dye and [89Zr]zirconium dual-labeled intercellular adhesion molecule 1 (ICAM-1, CD54) monoclonal antibody (mAb) to the imaging of positron emission tomography (PET), near-infrared fluorescence (NIRF) and Cerenkov optics, aiming to provide a proof-of-concept for the in vivo multi-modality visualization of PcCa foci targeting the ICAM-1 in tumor tissue. Methods: The difference between the expressions of ICAM-1 in BXPC-3 and ASPC-1 PcCa cell lines were tested by flow cytometry and immuno-fluorescent confocal imaging. Then we synthesized the 800CW/89Zr-ICAM-1 mAb tracer by bio-conjugation chemistry. The efficacy and specificity of 800CW/89Zr-ICAM-1 mAb were confirmed by the comparative in vivo PET/NIRF/Cerenkov imaging in the nude mice bearing subcutaneous (s.c.) BXPC-3 and ASPC-1 tumors, plus the imaging in the same modalities using the 800CW/89Zr-labeled non-specific IgG protein, followed by bio-distribution studies. Apart from that, the imaging function of 800CW/89Zr-ICAM-1 mAb was also validated in the orthotopic BXPC-3 tumor model by in vivo PET and ex vivo NIRF/Cerenkov optical imaging. Finally, the histo-pathological assay was conducted to characterize the ICAM-1 distribution in PcCa tumor tissues. Results: The expression contrast of ICAM-1 in the BXPC-3 (positive) and ASPC-1 (negative) cell lines is evident. The data of multi-modality imaging and bio-distribution indicated that the uptake in s.c. BCPX-3 is more prominent than that in the s.c. ASPC-1 tumors, and the uptake of 800CW/89Zr-IgG in s.c. BXPC-3 tumors are similar to the uptake of 800CW/89Zr-ICAM-1 mAb in s.c. ASPC-1 tumors. These results demonstrated the fine avidity and specificity of the 800CW/89Zr-ICAM-1 mAb tracer. In the images of orthotopic BXPC-3 tumor model, the tumor foci can be delineated clearly in PET tomographs and the outlines of tumors are co-inside with each other in the ex vivo NIRF/Cerenkov images. In the confocal images, the profile of ICAM-1 expression in BXPC-3 tumor tissue is confirmed to be higher than in the ASPC-1 tumor tissue. Conclusions: Taken together, we reported the first example of PET/NIRF/Cerenkov imaging based on the NIRF dye and PET nuclide dual-labeled ICAM-1 mAb, which sets a paradigm for the multi-modality visualization of ICAM-1 expressed in PcCa and implies the potential of its further clinical translation.

Targeting the Insulin Growth Factor-1 Receptor with Fluorescent Antibodies Enables High Resolution Imaging of Human Pancreatic Cancer in Orthotopic Mouse Models

Fluorescent-Antibody Targeting of Insulin-Like Growth Factor-1 Receptor Visualizes Metastatic Human Colon Cancer in Orthotopic Mouse Models

Targeting Pancreatic Cancer with Magneto-Fluorescent Theranostic Gold Nanoshells.

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore

Initial Characterization in Orthotopic Cell Line Mouse Models

In Situ Immunofluorescence Imaging of Vital Human Pancreatic Tissue Using Fiber-Optic Microscopy

Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein

Multi-Modality Imaging-Monitored Creation of Rat Orthotopic Pancreatic Head Cancer with Obstructive Jaundice

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore

ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.

A Self-Calibrating Fluorescent-Photoacoustic Integrated Probe Enables Fast Visualizing Pancreatic Cancer and Imaging-Guided Tumor Surgery

Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery

Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles.

IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

Bioluminescence and Fluorescence Based 3-D Imaging of Tumor in a Spontaneous Pancreatic Tumor Model

Establishment of Red Fluorescent Protein Orthotopic Transplantation Nude Mice Metastasis Model of Pancreatic Cancer and Whole-Body Fluorescent Imaging

Lentivirus-Based DsRed-2-Transfected Pancreatic Cancer Cells for Deep in Vivo Imaging of Metastatic Disease

Identification and Validation of a New Peptide Targeting Pancreatic Beta Cells

A Novel Plectin/integrin-Targeted Bispecific Molecular Probe for Magnetic Resonance/near-Infrared Imaging of Pancreatic Cancer.

800CW Dye and 89zr Dual-labeled Antibody for the PET/NIRF/Cerenkov Multi-modality Imaging of ICAM-1 (CD54) in Pancreatic Cancer